Day One Biopharmaceuticals, Inc. Insider Trading Activity

Insider Trade Summary

1,202,518 shares gifted

Gift 9 txns

Insider Bender Jeremy

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Gift	Common Stock	148,312	$0.00	$0.00
Gift	Common Stock	148,312	$0.00	$0.00
Gift	Common Stock	74,328	$0.00	$0.00
Gift	Common Stock	74,328	$0.00	$0.00
Gift	Common Stock	199,202	$0.00	$0.00
Gift	Common Stock	179,417	$0.00	$0.00
Gift	Common Stock	179,417	$0.00	$0.00
holding	Common Stock	--	--	--
Gift	Common Stock	199,202	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,197 shares (Indirect, See Footnote); Common Stock — 1,408,285 shares (Indirect, By Bender Revocable Trust); Common Stock — 145,737 shares (Direct)

Footnotes (9)

1. F1. Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Jeremy Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees ("Bender Revocable Trust dated January 18, 2017").
2. F2. Represents shares held by the Jeremy Bender 2022 GRAT of which the Reporting Person is trustee.
3. F3. Represents shares held by the Bender Revocable Trust dated January 18, 2017.
4. F4. Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Melissa Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.
5. F5. Represents shares held by the Melissa Bender 2022 GRAT of which the Reporting Person's spouse is trustee.
6. F6. Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 ("Jeremy Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.
7. F7. Represents shares held by the Jeremy Bender 2023 GRAT.
8. F8. Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 ("Melissa Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.
9. F9. Represents shares held by the Melissa Bender 2023 GRAT.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2025 - 04:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bender Jeremy

(Last) (First) (Middle)

1800 SIERRA POINT PARKWAY, SUITE 200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Day One Biopharmaceuticals, Inc. [ DAWN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2025		G		148,312(1)	D	$0	14,450	I	See Footnote(2)
Common Stock	07/10/2025		G		148,312(1)	A	$0	955,338	I	By Bender Revocable Trust(3)
Common Stock	07/10/2025		G		74,328(4)	D	$0	147,702	I	See Footnote(5)
Common Stock	07/10/2025		G		74,328(4)	A	$0	1,029,666	I	By Bender Revocable Trust(3)
Common Stock	07/10/2025		G		199,202(6)	D	$0	20,204	I	See Footnote(7)
Common Stock	07/02/2024		G		199,202(6)	A	$0	1,228,868	I	By Bender Revocable Trust(3)
Common Stock	07/10/2025		G		179,417(8)	D	$0	18,197	I	See Footnote(9)
Common Stock	07/10/2025		G		179,417(8)	A	$0	1,408,285	I	By Bender Revocable Trust(3)
Common Stock								145,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Jeremy Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees ("Bender Revocable Trust dated January 18, 2017").

2. Represents shares held by the Jeremy Bender 2022 GRAT of which the Reporting Person is trustee.

3. Represents shares held by the Bender Revocable Trust dated January 18, 2017.

4. Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 ("Melissa Bender 2022 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.

5. Represents shares held by the Melissa Bender 2022 GRAT of which the Reporting Person's spouse is trustee.

6. Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 ("Jeremy Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.

7. Represents shares held by the Jeremy Bender 2023 GRAT.

8. Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 ("Melissa Bender 2023 GRAT"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017.

9. Represents shares held by the Melissa Bender 2023 GRAT.

	/s/ Charles N. York II, Attorney-in-Fact	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.